WO2003051306A3 - N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections - Google Patents
N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections Download PDFInfo
- Publication number
- WO2003051306A3 WO2003051306A3 PCT/US2002/040090 US0240090W WO03051306A3 WO 2003051306 A3 WO2003051306 A3 WO 2003051306A3 US 0240090 W US0240090 W US 0240090W WO 03051306 A3 WO03051306 A3 WO 03051306A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acylcytosine
- viral infections
- treatment
- dioxolane nucleosides
- dioxolane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002364730A AU2002364730A1 (en) | 2001-12-14 | 2002-12-16 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34155501P | 2001-12-14 | 2001-12-14 | |
US60/341,555 | 2001-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003051306A2 WO2003051306A2 (en) | 2003-06-26 |
WO2003051306A3 true WO2003051306A3 (en) | 2003-12-18 |
Family
ID=23338072
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/040081 WO2003063771A2 (en) | 2001-12-14 | 2002-12-13 | N4-acylcytosine nucleosides for treatment of viral iinfections |
PCT/US2002/040090 WO2003051306A2 (en) | 2001-12-14 | 2002-12-16 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/040081 WO2003063771A2 (en) | 2001-12-14 | 2002-12-13 | N4-acylcytosine nucleosides for treatment of viral iinfections |
Country Status (10)
Country | Link |
---|---|
US (6) | US7105527B2 (en) |
EP (1) | EP1569652A4 (en) |
JP (1) | JP2005519916A (en) |
KR (1) | KR100978904B1 (en) |
CN (1) | CN100560073C (en) |
AU (2) | AU2002365234B2 (en) |
BR (1) | BR0214944A (en) |
CA (1) | CA2470255C (en) |
MX (1) | MXPA04005779A (en) |
WO (2) | WO2003063771A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
EP1284741B1 (en) | 2000-04-13 | 2008-11-19 | Pharmasset, Inc. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN101099745A (en) * | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | Methods and compositions for treating flaviviruses and pestiviruses |
CN100560073C (en) * | 2001-12-14 | 2009-11-18 | 法玛塞特公司 | The N that is used for the treatment of viral infection 4-acyl group cytidine |
CN101172993A (en) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
RS113904A (en) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
EP1545545A4 (en) | 2002-08-01 | 2008-09-03 | Pharmasset Inc | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
US7598373B2 (en) * | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
CA2425031A1 (en) * | 2003-04-01 | 2004-10-01 | Smithkline Beecham Corporation | Pharmaceutical compositions |
KR100883703B1 (en) * | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | Modified fluorinated nucleoside analogues |
US7741334B2 (en) * | 2004-04-01 | 2010-06-22 | Achillion Pharmaceuticals, Inc. | Low dose therapy for treating viral infections |
CN101023094B (en) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
SI3109244T1 (en) | 2004-09-14 | 2019-06-28 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
EP1802315A2 (en) * | 2004-10-19 | 2007-07-04 | Achillion Pharmaceuticals, Inc. | Combination therapy for treating viral infections |
US7968703B2 (en) * | 2005-03-07 | 2011-06-28 | Shire Canada Inc. | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof |
CA2634749C (en) * | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
PL3290428T3 (en) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
CL2011000716A1 (en) | 2010-03-31 | 2012-04-20 | Gilead Pharmasset Llc | Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection. |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
HUE036588T2 (en) | 2011-09-16 | 2018-07-30 | Gilead Pharmasset Llc | Methods for treating hcv |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CN103242400B (en) * | 2012-02-08 | 2016-06-08 | 河南师范大学 | There is 5-substituted pyrimidines nucleoside-thiazolidhybrid hybrid and its preparation method of HIV (human immunodeficiency virus)-resistant activity |
MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
EP3265102A4 (en) | 2015-03-06 | 2018-12-05 | ATEA Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
KR20190043602A (en) | 2016-09-07 | 2019-04-26 | 아테아 파마슈티컬즈, 인크. | 2'-substituted-N6-substituted purine nucleotides for the treatment of RNA viruses |
SG11201906163TA (en) | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
CN112351799A (en) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | Treatment of HCV infected patients with cirrhosis |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922867A (en) * | 1995-12-14 | 1999-07-13 | Biochem Pharma Inc. | Method and compositions for the synthesis of dioxolane nucleosides with β configuration |
US20030013660A1 (en) * | 2000-10-13 | 2003-01-16 | Shire Biochem Inc. | Dioxolane analogs for improved inter-cellular delivery |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US13660A (en) * | 1855-10-09 | Improvements | ||
US3309359A (en) * | 1965-10-22 | 1967-03-14 | Hoffmann La Roche | N-mono-acyl-5-fluorocytosine derivatives and process |
NL8202626A (en) | 1982-06-29 | 1984-01-16 | Stichting Rega V Z W | DERIVATIVES OF 9- (2-HYDROXYETHOXYMETHYL) GUANINE. |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
ZA886890B (en) * | 1987-10-09 | 1989-05-30 | Hoffmann La Roche | Novel dideoxycytidine derivatives |
US6350753B1 (en) * | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
NL8901258A (en) | 1989-05-19 | 1990-12-17 | Stichting Rega V Z W | New 5-halo-2'-3'-di:deoxy-cytidine derivs. - useful as anti-retro-viral agents, esp. for treating HIV infections |
DD293498A5 (en) | 1989-07-20 | 1991-09-05 | Zi Fuer Molekularbiologie Der Adw,De | METHOD FOR PRODUCING A MEDIUM FOR THE TREATMENT OR PROPHYLAXIS OF HEPATITE INFECTIONS IN HUMANS AND ANIMALS |
JPH05310777A (en) | 1992-05-14 | 1993-11-22 | Yoshitomi Pharmaceut Ind Ltd | 2'-deoxy-2'-methylidynecytidine compound |
TW254946B (en) * | 1992-12-18 | 1995-08-21 | Hoffmann La Roche | |
TW374087B (en) * | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
AU4988697A (en) * | 1996-10-24 | 1998-05-15 | Vion Pharmaceuticals, Inc. | Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents |
AU1412299A (en) * | 1997-11-25 | 1999-06-15 | Protarga, Inc. | Nucleoside analog compositions and uses thereof |
ES2276515T3 (en) * | 1998-02-25 | 2007-06-16 | Emory University | 2'-FLUORONUCLEOSIDS. |
KR20090089922A (en) * | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
CN100560073C (en) * | 2001-12-14 | 2009-11-18 | 法玛塞特公司 | The N that is used for the treatment of viral infection 4-acyl group cytidine |
-
2002
- 2002-12-13 CN CNB028278402A patent/CN100560073C/en not_active Expired - Fee Related
- 2002-12-13 JP JP2003563467A patent/JP2005519916A/en active Pending
- 2002-12-13 WO PCT/US2002/040081 patent/WO2003063771A2/en active Application Filing
- 2002-12-13 MX MXPA04005779A patent/MXPA04005779A/en active IP Right Grant
- 2002-12-13 EP EP02804833A patent/EP1569652A4/en not_active Withdrawn
- 2002-12-13 US US10/318,511 patent/US7105527B2/en not_active Expired - Fee Related
- 2002-12-13 AU AU2002365234A patent/AU2002365234B2/en not_active Ceased
- 2002-12-13 CA CA2470255A patent/CA2470255C/en not_active Expired - Fee Related
- 2002-12-13 BR BR0214944-3A patent/BR0214944A/en not_active Application Discontinuation
- 2002-12-13 KR KR1020047009263A patent/KR100978904B1/en not_active IP Right Cessation
- 2002-12-16 AU AU2002364730A patent/AU2002364730A1/en not_active Abandoned
- 2002-12-16 US US10/320,350 patent/US6908924B2/en not_active Ceased
- 2002-12-16 WO PCT/US2002/040090 patent/WO2003051306A2/en not_active Application Discontinuation
-
2006
- 2006-07-31 US US11/461,338 patent/US20070078080A1/en not_active Abandoned
-
2007
- 2007-06-21 US US11/821,076 patent/USRE42015E1/en not_active Expired - Fee Related
-
2008
- 2008-01-04 US US11/969,427 patent/US8114997B2/en not_active Expired - Fee Related
-
2012
- 2012-02-13 US US13/371,654 patent/US20120202766A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922867A (en) * | 1995-12-14 | 1999-07-13 | Biochem Pharma Inc. | Method and compositions for the synthesis of dioxolane nucleosides with β configuration |
US20030013660A1 (en) * | 2000-10-13 | 2003-01-16 | Shire Biochem Inc. | Dioxolane analogs for improved inter-cellular delivery |
Also Published As
Publication number | Publication date |
---|---|
USRE42015E1 (en) | 2010-12-28 |
JP2005519916A (en) | 2005-07-07 |
US20070078080A1 (en) | 2007-04-05 |
US8114997B2 (en) | 2012-02-14 |
US20040214844A1 (en) | 2004-10-28 |
WO2003063771A3 (en) | 2005-07-07 |
CA2470255A1 (en) | 2003-08-07 |
US20030176319A1 (en) | 2003-09-18 |
EP1569652A4 (en) | 2008-07-02 |
AU2002364730A8 (en) | 2003-06-30 |
KR100978904B1 (en) | 2010-08-31 |
WO2003063771A2 (en) | 2003-08-07 |
CN1617726A (en) | 2005-05-18 |
CA2470255C (en) | 2012-01-17 |
US7105527B2 (en) | 2006-09-12 |
AU2002365234B2 (en) | 2009-01-29 |
EP1569652A2 (en) | 2005-09-07 |
AU2002364730A1 (en) | 2003-06-30 |
CN100560073C (en) | 2009-11-18 |
MXPA04005779A (en) | 2005-05-16 |
BR0214944A (en) | 2005-06-07 |
KR20040094398A (en) | 2004-11-09 |
US20090176730A1 (en) | 2009-07-09 |
US6908924B2 (en) | 2005-06-21 |
WO2003051306A2 (en) | 2003-06-26 |
US20120202766A1 (en) | 2012-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003051306A3 (en) | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | |
WO2001090121A3 (en) | Methods and compositions for treating hepatitis c virus | |
WO2003026589A3 (en) | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides | |
WO2004046159A8 (en) | Antiviral nucleoside derivatives | |
WO2001060315A3 (en) | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | |
WO2007038507A3 (en) | Modified 4'-nucleosides as antiviral agents | |
WO2002100415A3 (en) | 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
BR0111195A (en) | Use of b-1,2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection | |
MY128463A (en) | 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
WO2001032153A3 (en) | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues | |
WO1998001144A2 (en) | Antiviral agents from plant extracts and use for treatment of viral infections | |
EP1808434A3 (en) | Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B | |
WO2006044968A3 (en) | Combination therapy for treating viral infections | |
WO2001010456A3 (en) | Peptides that block viral infectivity and methods of use thereof | |
WO2006045616A3 (en) | β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | |
WO2005097618A3 (en) | Low dose therapy for treating viral infections | |
WO2004052905A3 (en) | Antiviral nucleoside derivatives | |
WO2004043402A3 (en) | Modified nucleosides as antiviral agents | |
RU93058325A (en) | APPLICATION OF 1,3-OXATHIOLANE DERIVATIVES FOR PRODUCTION OF MEDICINES FOR THE TREATMENT OR PREVENTION OF HEPATITIS B VIRAL INFECTION, APPLICATION OF 1,3 - OXATHYOLANE DERIVATIVES FOR THE TREATMENT OF HEPATITIS | |
WO2004013298A3 (en) | 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections | |
WO2004006848A3 (en) | Combination therapies with ftc for the treatment of hepatitis b virus infection | |
WO2002009677A3 (en) | Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs | |
AU2001274661A1 (en) | Therapeutic vaccine preparation and treatment for hiv viral infection | |
MY113560A (en) | Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |